8-K: Bone Biologics Implements 1-for-6 Reverse Stock Split to Consolidate Shares

Bone Biologics Corporation has announced a 1-for-6 reverse stock split of its common stock, effective June 10, 2025, aiming to consolidate shares and potentially address Nasdaq listing requirements.

Summary

• Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-6 reverse stock split of its common stock.
• The reverse stock split will become effective at 12:01 a.m. Eastern Time on June 10, 2025.
• Common stock is expected to begin trading on a post-split basis under the existing symbol BBLG when the market opens on June 10, 2025.
• Every 6 shares of common stock outstanding immediately prior to the effective time will be automatically combined into one share of common stock.
• Fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
• The total number of authorized shares of common stock will remain at 100,000,000, and preferred stock at 20,000,000, with a par value of $0.001 per share for both.
• Proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of warrants and under equity plans.
• The reverse stock split will not change the par value of the common stock or modify any voting rights or other terms.
• Stockholders approved an amendment to the Certificate of Incorporation at the annual meeting on May 30, 2025, granting the board authority to implement a reverse stock split within a range of 1-for-2.5 to 1-for-10, with the board subsequently setting the ratio at 1-for-6.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative. While the reverse stock split is a necessary action to maintain Nasdaq listing and avoid delisting, the underlying reason for such a split (a low stock price) reflects past poor performance or market perception. The action itself doesn't fundamentally improve the company's business operations or financial health, but it addresses a critical compliance issue.

Positives

• The reverse stock split is a necessary corporate action that can help the company maintain compliance with Nasdaq's minimum bid price requirements, ensuring continued listing on a major exchange.
• Fractional shares resulting from the split will be rounded up to the nearest whole share, which benefits stockholders who would otherwise receive fractional interests.

Negatives

• A reverse stock split is often indicative of a low stock price, which typically reflects underlying financial weakness or lack of investor confidence in the company's current valuation.
• While percentage ownership remains unchanged, the reduction in the number of outstanding shares can sometimes be perceived negatively by investors, potentially impacting liquidity.

Risks

• The company's actual results may differ materially from forward-looking statements due to market and other conditions.
• Risks are generally associated with an undercapitalized developing company.
• Other risks are contained under 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and other SEC filings.

Future Outlook

The company expects the common stock to begin trading on a post-split basis under its existing trading symbol, BBLG, when the market opens on June 10, 2025. Forward-looking statements indicate the company anticipates the timing, implementation, and success of the reverse stock split.

Management Comments

• Jeffrey Frelick, Chief Executive Officer, signed the filing on behalf of Bone Biologics Corporation.

Industry Context

Bone Biologics Corporation is a developer of orthobiologic products, specifically focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures. The company also holds rights to trauma and osteoporosis applications. The reverse stock split is a corporate finance action, not directly related to product development, but it impacts the company's standing in the capital markets, which is crucial for a developing company in the medical technology sector.

Comparison to Industry Standards

• The document does not provide specific financial or operational results that allow for direct comparison to industry benchmarks or specific comparable companies/projects. The reverse stock split is a corporate action often undertaken by companies with low stock prices, which is a common challenge for smaller, developing companies in the biotech/medtech space that are pre-revenue or early-revenue stage.

Corporate Governance

Stakeholder Impact

• Shareholders: Will hold fewer shares but their percentage ownership interest in Bone Biologics will remain unchanged. Fractional shares will be rounded up to the nearest whole share.
• Warrant Holders and Equity Award Holders: The per-share exercise price and the number of shares issuable upon exercise will be proportionately adjusted to reflect the split.

Next Steps

• The common stock will begin trading on a post-split basis under the symbol BBLG when the market opens on June 10, 2025.

Key Dates

Recommendation

Keywords

Reverse Stock Split, Bone Biologics, BBLG, Nasdaq, Corporate Action, Share Consolidation, Orthobiologics, Spine Fusion, SEC Filing, Form 8-K